Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, today announced it has signed a definitive agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey. This acquisition will significantly enhance Ardena’s capabilities in downstream late-stage and small-scale commercial manufacturing of oral drug products, supporting its strategy to become a leading global CDMO offering integrated solutions across the entire pharmaceutical development lifecycle. The FDA-approved Somerset facility employs approximately 200 skilled scientists and technicians and is a Center of Excellence for advanced delivery of oral dosage forms.
Read the full article: Ardena Signs Agreement to Expand US Footprint with the Acquisition of Advanced Drug Product Manufacturing Facility from Catalent //
Source: https://www.globenewswire.com/news-release/2024/10/14/2962407/0/en/Ardena-Signs-Agreement-to-Expand-US-Footprint-with-the-Acquisition-of-Advanced-Drug-Product-Manufacturing-Facility-from-Catalent.html